{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:16:37Z","timestamp":1791839797350,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40257-020-00580-6","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T14:02:21Z","timestamp":1608645741000},"page":"149-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["The Growing Problem of Antifungal Resistance in Onychomycosis and Other Superficial Mycoses"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":false,"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen J.","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M.","family":"Quinlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil H.","family":"Shear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"580_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.4103\/ijdvl.IJDVL_224_17","volume":"83","author":"S Panda","year":"2017","unstructured":"Panda S, Verma S. The menace of dermatophytosis in India: the evidence that we need. Indian J Dermatol Venereol Leprol. 2017;83:281\u20134. https:\/\/doi.org\/10.4103\/ijdvl.IJDVL_224_17.","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"580_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4103\/ijd.IJD_206_17","volume":"62","author":"S Verma","year":"2017","unstructured":"Verma S, Madhu R. The Great Indian epidemic of superficial dermatophytosis: an appraisal. Indian J Dermatol. 2017;62:227\u201336. https:\/\/doi.org\/10.4103\/ijd.IJD_206_17.","journal-title":"Indian J Dermatol."},{"key":"580_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1439-0507.2008.01606.x","volume":"51","author":"B Havlickova","year":"2008","unstructured":"Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51:2\u201315. https:\/\/doi.org\/10.1111\/j.1439-0507.2008.01606.x.","journal-title":"Mycoses"},{"key":"580_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1128\/MMBR.00016-10","volume":"74","author":"J Davies","year":"2010","unstructured":"Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev MMBR. 2010;74:417\u201333. https:\/\/doi.org\/10.1128\/MMBR.00016-10.","journal-title":"Microbiol Mol Biol Rev MMBR."},{"key":"580_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s11046-008-9100-9","volume":"166","author":"C Seebacher","year":"2008","unstructured":"Seebacher C, Bouchara J-P, Mignon B. Updates on the epidemiology of dermatophyte infections. Mycopathologia. 2008;166:335\u201352. https:\/\/doi.org\/10.1007\/s11046-008-9100-9.","journal-title":"Mycopathologia"},{"key":"580_CR6","first-page":"281","volume":"69","author":"S Singh","year":"2003","unstructured":"Singh S, Beena PM. Profile of dermatophyte infections in Baroda. Indian J Dermatol Venereol Leprol. 2003;69:281\u20133.","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"580_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/myc.12878","volume":"62","author":"P Nenoff","year":"2019","unstructured":"Nenoff P, Verma SB, Vasani R, Burmester A, Hipler U-C, Wittig F, Kr\u00fcger C, Nenoff K, Wiegand C, Saraswat A, Madhu R, Panda S, Das A, Kura M, Jain A, Koch D, Gr\u00e4ser Y, Uhrla\u00df S. The current Indian epidemic of superficial dermatophytosis due to Trichophyton mentagrophytes-a molecular study. Mycoses. 2019;62:336\u201356. https:\/\/doi.org\/10.1111\/myc.12878.","journal-title":"Mycoses"},{"key":"580_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1540-9740.2005.03435.x","volume":"4","author":"AK Gupta","year":"2005","unstructured":"Gupta AK, Ryder JE, Chow M, Cooper EA. Dermatophytosis: the management of fungal infections. Skinmed. 2005;4:305\u201310.","journal-title":"Skinmed."},{"key":"580_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1128\/AAC.47.1.82-86.2003","volume":"47","author":"PK Mukherjee","year":"2003","unstructured":"Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS, Ghannoum MA. Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob Agents Chemother. 2003;47:82\u20136.","journal-title":"Antimicrob Agents Chemother."},{"key":"580_CR10","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1128\/AAC.01600-05","volume":"50","author":"CS Osborne","year":"2006","unstructured":"Osborne CS, Leitner I, Hofbauer B, Fielding CA, Favre B, Ryder NS. Biological, biochemical, and molecular characterization of a new clinical Trichophyton rubrum isolate resistant to terbinafine. Antimicrob Agents Chemother. 2006;50:2234\u20136. https:\/\/doi.org\/10.1128\/AAC.01600-05.","journal-title":"Antimicrob Agents Chemother."},{"key":"580_CR11","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/myc.12772","volume":"61","author":"A Singh","year":"2018","unstructured":"Singh A, Masih A, Khurana A, Singh PK, Gupta M, Hagen F, Meis JF, Chowdhary A. High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses. 2018;61:477\u201384. https:\/\/doi.org\/10.1111\/myc.12772.","journal-title":"Mycoses"},{"key":"580_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00115-17","author":"T Yamada","year":"2017","unstructured":"Yamada T, Maeda M, Alshahni MM, Tanaka R, Yaguchi T, Bontems O, Salamin K, Fratti M, Monod M. Terbinafine resistance of trichophyton clinical isolates caused by specific point mutations in the squalene epoxidase gene. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.00115-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"580_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02522-17","author":"SM Rudramurthy","year":"2018","unstructured":"Rudramurthy SM, Shankarnarayan SA, Dogra S, Shaw D, Mushtaq K, Paul RA, Narang T, Chakrabarti A. Mutation in the squalene epoxidase gene of Trichophyton interdigitale and Trichophyton rubrum associated with allylamine resistance. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.02522-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"580_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/1346-8138.14809","volume":"46","author":"J Hiruma","year":"2019","unstructured":"Hiruma J, Kitagawa H, Noguchi H, Kano R, Hiruma M, Kamata H, Harada K. Terbinafine-resistant strain of Trichophyton interdigitale strain isolated from a tinea pedis patient. J Dermatol. 2019;46:351\u20133. https:\/\/doi.org\/10.1111\/1346-8138.14809.","journal-title":"J Dermatol."},{"key":"580_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.mmcr.2019.09.001","volume":"26","author":"A Burmester","year":"2019","unstructured":"Burmester A, Hipler U-C, Hensche R, Elsner P, Wiegand C. Point mutations in the squalene epoxidase gene of Indian ITS genotype VIII T. mentagrophytes identified after DNA isolation from infected scales. Med Mycol Case Rep. 2019;26:23\u20134. https:\/\/doi.org\/10.1016\/j.mmcr.2019.09.001.","journal-title":"Med Mycol Case Rep."},{"key":"580_CR16","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.mycmed.2019.100903","volume":"29","author":"A Hsieh","year":"2019","unstructured":"Hsieh A, Quenan S, Riat A, Toutous-Trellu L, Fontao L. A new mutation in the SQLE gene of Trichophyton mentagrophytes associated to terbinafine resistance in a couple with disseminated tinea corporis. J Mycol Med. 2019;29:352\u20135. https:\/\/doi.org\/10.1016\/j.mycmed.2019.100903.","journal-title":"J Mycol Med."},{"key":"580_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01126-19","author":"DML Saunte","year":"2019","unstructured":"Saunte DML, Hare RK, J\u00f8rgensen KM, J\u00f8rgensen R, Deleuran M, Zachariae CO, Thomsen SF, Bj\u00f8rnskov-Halkier L, Kofoed K, Arendrup MC. Emerging terbinafine resistance in trichophyton: clinical characteristics, squalene epoxidase gene mutations, and a reliable EUCAST method for detection. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/AAC.01126-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"580_CR18","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s00105-019-4431-7","volume":"70","author":"A S\u00fc\u00df","year":"2019","unstructured":"S\u00fc\u00df A, Uhrla\u00df S, Ludes A, Verma SB, Monod M, Kr\u00fcger C, Nenoff P. Extensive tinea corporis due to a terbinafine-resistant Trichophyton mentagrophytes isolate of the Indian genotype in a young infant from Bahrain in Germany. Hautarzt Z Dermatol Venerol Verwandte Geb. 2019;70:888\u201396. https:\/\/doi.org\/10.1007\/s00105-019-4431-7.","journal-title":"Hautarzt Z Dermatol Venerol Verwandte Geb."},{"key":"580_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19146","author":"S Singh","year":"2020","unstructured":"Singh S, Chandra U, Anchan VN, Verma P, Tilak R. Limited effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole and terbinafine) in the current epidemic of altered dermatophytosis in India: results of a randomized pragmatic trial. Br J Dermatol. 2020. https:\/\/doi.org\/10.1111\/bjd.19146.","journal-title":"Br J Dermatol."},{"key":"580_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/myc.13091","volume":"63","author":"A Ebert","year":"2020","unstructured":"Ebert A, Monod M, Salamin K, Burmester A, Uhrla\u00df S, Wiegand C, Hipler U-C, Kr\u00fcger C, Koch D, Wittig F, Verma SB, Singal A, Gupta S, Vasani R, Saraswat A, Madhu R, Panda S, Das A, Kura MM, Kumar A, Poojary S, Schirm S, Gr\u00e4ser Y, Paasch U, Nenoff P. Alarming India-wide phenomenon of antifungal resistance in dermatophytes: a multicentre study. Mycoses. 2020;63:717\u201328. https:\/\/doi.org\/10.1111\/myc.13091.","journal-title":"Mycoses"},{"key":"580_CR21","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s10096-018-3317-4","volume":"37","author":"Z Salehi","year":"2018","unstructured":"Salehi Z, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M. Antifungal drug susceptibility profile of clinically important dermatophytes and determination of point mutations in terbinafine-resistant isolates. Eur J Clin Microbiol Infect Dis. 2018;37:1841\u20136. https:\/\/doi.org\/10.1007\/s10096-018-3317-4.","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"580_CR22","unstructured":"J\u00e4rv H, Uhrlass S, Simkin T, Nenoff E, Alvarado Ramirez E, Chryssanthou E, Monod M. Terbinafine resistant Trichophyton mentagrophytes genotype VIII, Indian type, isolated in Finland. In: 9th Trends Med. Mycol. Held 11-14 Oct. 2019 Nice Fr. Organ. Auspices EORTC-IDG ECMM, Journal of Fungi, Nice, France, 2019: p. P039."},{"key":"580_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.mmcr.2017.07.003","volume":"18","author":"JG Gallo","year":"2017","unstructured":"Gallo JG, Woods M, Graham RM, Jennison AV. A severe transmissible Majocchi\u2019s granuloma in an immunocompetent returned traveler. Med Mycol Case Rep. 2017;18:5\u20137. https:\/\/doi.org\/10.1016\/j.mmcr.2017.07.003.","journal-title":"Med Mycol Case Rep."},{"key":"580_CR24","doi-asserted-by":"publisher","unstructured":"Rengasamy M, Shenoy MM, Dogra S, Asokan N, Khurana A, Poojary S, Jayaraman J, Valia AR, Sardana K, Kolalapudi S, Marfatia Y, Rao PN, Bhat RM, Kura M, Pandhi D, Barua S, Kaushal V. Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task Force against Recalcitrant Tinea (ITART) Consensus on the Management of Glabrous Tinea (INTACT). 2020;11:502\u201319. Indian Dermatol Online J. https:\/\/doi.org\/10.4103\/idoj.IDOJ_233_20.","DOI":"10.4103\/idoj.IDOJ_233_20"},{"key":"580_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.4103\/0019-5154.190120","volume":"61","author":"I Majid","year":"2016","unstructured":"Majid I, Sheikh G, Kanth F, Hakak R. Relapse after oral terbinafine therapy in dermatophytosis: a clinical and mycological study. Indian J Dermatol. 2016;61:529\u201333. https:\/\/doi.org\/10.4103\/0019-5154.190120.","journal-title":"Indian J Dermatol."},{"key":"580_CR26","doi-asserted-by":"publisher","first-page":"554","DOI":"10.4103\/ijdvl.IJDVL_526_17","volume":"84","author":"S Singh","year":"2018","unstructured":"Singh S, Shukla P. End of the road for terbinafine? Results of a pragmatic prospective cohort study of 500 patients. Indian J Dermatol Venereol Leprol. 2018;84:554\u20137. https:\/\/doi.org\/10.4103\/ijdvl.IJDVL_526_17.","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"580_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01038-18","author":"A Khurana","year":"2018","unstructured":"Khurana A, Masih A, Chowdhary A, Sardana K, Borker S, Gupta A, Gautam RK, Sharma PK, Jain D. Correlation of in vitro susceptibility based on MICs and squalene epoxidase mutations with clinical response to terbinafine in patients with tinea corporis\/cruris. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.01038-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"580_CR28","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2147\/IDR.S246025","volume":"13","author":"S Taghipour","year":"2020","unstructured":"Taghipour S, Shamsizadeh F, Pchelin IM, Rezaei-Matehhkolaei A, Zarei Mahmoudabadi A, Valadan R, Ansari S, Katiraee F, Pakshir K, Zomorodian K, Abastabar M. Emergence of terbinafine resistant trichophyton mentagrophytes in Iran, harboring mutations in the squalene epoxidase (SQLE) gene. Infect Drug Resist. 2020;13:845\u201350. https:\/\/doi.org\/10.2147\/IDR.S246025.","journal-title":"Infect Drug Resist"},{"key":"580_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14014","author":"A Nofal","year":"2020","unstructured":"Nofal A, Fawzy MM, El-Hawary EE. Successful treatment of resistant onychomycosis with voriconazole in a liver transplant patient. Dermatol Ther. 2020. https:\/\/doi.org\/10.1111\/dth.14014.","journal-title":"Dermatol Ther"},{"key":"580_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/pde.13411","volume":"35","author":"L Sch\u00f8sler","year":"2018","unstructured":"Sch\u00f8sler L, Andersen LK, Arendrup MC, Sommerlund M. Recurrent terbinafine resistant Trichophyton rubrum infection in a child with congenital ichthyosis. Pediatr Dermatol. 2018;35:259\u201360. https:\/\/doi.org\/10.1111\/pde.13411.","journal-title":"Pediatr Dermatol."},{"key":"580_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2340\/00015555-2455","volume":"97","author":"SS Digby","year":"2017","unstructured":"Digby SS, Hald M, Arendrup MC, Hjort SV, Kofoed K. Darier disease complicated by terbinafine-resistant Trichophyton rubrum: a case report. Acta Dermatol Venereol. 2017;97:139\u201340. https:\/\/doi.org\/10.2340\/00015555-2455.","journal-title":"Acta Dermatol Venereol."},{"key":"580_CR32","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/mmy\/myx044","volume":"56","author":"HL Santos","year":"2018","unstructured":"Santos HL, Lang EAS, Segato F, Rossi A, Martinez-Rossi NM. Terbinafine resistance conferred by multiple copies of the salicylate 1-monooxygenase gene in Trichophyton rubrum. Med Mycol. 2018;56:378\u201381. https:\/\/doi.org\/10.1093\/mmy\/myx044.","journal-title":"Med Mycol."},{"key":"580_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19420","author":"E Chen","year":"2020","unstructured":"Chen E, Ghannoum M, Elewski BE. Treatment-resistant tinea corporis, a potential public health issue. Br J Dermatol. 2020. https:\/\/doi.org\/10.1111\/bjd.19420.","journal-title":"Br J Dermatol"},{"key":"580_CR34","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/myc.12794","volume":"61","author":"A Gawaz","year":"2018","unstructured":"Gawaz A, Weisel G. Mixed infections are a critical factor in the treatment of superficial mycoses. Mycoses. 2018;61:731\u20135. https:\/\/doi.org\/10.1111\/myc.12794.","journal-title":"Mycoses"},{"key":"580_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16394","author":"AK Gupta","year":"2020","unstructured":"Gupta AK, Stec N, Summerbell RC, Shear NH, Piguet V, Tosti A, Piraccini BM. Onychomycosis: a review. J Eur Acad Dermatol Venereol JEADV. 2020. https:\/\/doi.org\/10.1111\/jdv.16394.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"key":"580_CR36","first-page":"49","volume":"2","author":"JG Newland","year":"2009","unstructured":"Newland JG, Abdel-Rahman SM. Update on terbinafine with a focus on dermatophytoses. Clin Cosmet Investig Dermatol CCID. 2009;2:49\u201363.","journal-title":"Clin Cosmet Investig Dermatol CCID."},{"key":"580_CR37","unstructured":"Novartis Pharmaceuticals Corporation. Product monograph Lamisil (terbinafine hydrochloride). 2011. http:\/\/webprod3.hc-sc.gc.ca\/dpd-bdpp\/info.do?lang=eng&code=13990. Accessed 21 Aug 2012."},{"key":"580_CR38","doi-asserted-by":"crossref","unstructured":"Gupta AK, Taborda VBA, Taborda PRO, Shemer A, Nakrieko K-A. High prevalence of mixed infections in global onychomycosis. 2020.","DOI":"10.1371\/journal.pone.0239648"},{"key":"580_CR39","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/09546634.2019.1612835","volume":"31","author":"P Sharma","year":"2020","unstructured":"Sharma P, Bhalla M, Thami GP, Chander J. Evaluation of efficacy and safety of oral terbinafine and itraconazole combination therapy in the management of dermatophytosis. J Dermatol Treat. 2020;31:749\u201353. https:\/\/doi.org\/10.1080\/09546634.2019.1612835.","journal-title":"J Dermatol Treat."},{"key":"580_CR40","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/jac\/dkaa111","volume":"75","author":"MC Arendrup","year":"2020","unstructured":"Arendrup MC, J\u00f8rgensen KM, Guinea J, Lagrou K, Chryssanthou E, Hayette M-P, Barchiesi F, Lass-Fl\u00f6rl C, Hamal P, Dannaoui E, Chowdhary A, Meletiadis J. Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. J Antimicrob Chemother. 2020;75:1807\u201319. https:\/\/doi.org\/10.1093\/jac\/dkaa111.","journal-title":"J Antimicrob Chemother."},{"issue":"Suppl 1","key":"580_CR41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1439-0507.2006.01295.x","volume":"49","author":"H Hof","year":"2006","unstructured":"Hof H. A new, broad-spectrum azole antifungal: posaconazole\u2013mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49(Suppl 1):2\u20136. https:\/\/doi.org\/10.1111\/j.1439-0507.2006.01295.x.","journal-title":"Mycoses"},{"key":"580_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11046-016-0045-0","volume":"182","author":"AK Gupta","year":"2017","unstructured":"Gupta AK, Foley KA, Versteeg SG. New antifungal agents and new formulations against dermatophytes. Mycopathologia. 2017;182:127\u201341. https:\/\/doi.org\/10.1007\/s11046-016-0045-0.","journal-title":"Mycopathologia"},{"key":"580_CR43","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ijantimicag.2017.03.021","volume":"50","author":"R Hachem","year":"2017","unstructured":"Hachem R, Assaf A, Numan Y, Shah P, Jiang Y, Chaftari A-M, Raad II. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies. Int J Antimicrob Agents. 2017;50:384\u20138. https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.03.021.","journal-title":"Int J Antimicrob Agents."},{"key":"580_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/IDR.S61998","volume":"9","author":"AK Gupta","year":"2016","unstructured":"Gupta AK, Daigle D. A critical appraisal of once-daily topical luliconazole for the treatment of superficial fungal infections. Infect Drug Resist. 2016;9:1\u20136. https:\/\/doi.org\/10.2147\/IDR.S61998.","journal-title":"Infect Drug Resist."},{"key":"580_CR45","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1128\/AAC.02056-12","volume":"57","author":"WJ Jo Siu","year":"2013","unstructured":"Jo Siu WJ, Tatsumi Y, Senda H, Pillai R, Nakamura T, Sone D, Fothergill A. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother. 2013;57:1610\u20136. https:\/\/doi.org\/10.1128\/AAC.02056-12.","journal-title":"Antimicrob Agents Chemother"},{"key":"580_CR46","unstructured":"Valeant Canada LP. PrJubliaTM Efinaconazole Topical Solution, 10% w\/w Topical Antifungal Agent. 2017. https:\/\/pdf.hres.ca\/dpd_pm\/00040037.PDF. Accessed 03 Mar 2020."},{"key":"580_CR47","first-page":"609","volume":"14","author":"D Coronado","year":"2015","unstructured":"Coronado D, Merchant T, Chanda S, Zane LT. In vitro nail penetration and antifungal activity of tavaborole, a boron-based pharmaceutical. J Drugs Dermatol JDD. 2015;14:609\u201314.","journal-title":"J Drugs Dermatol JDD."},{"key":"580_CR48","unstructured":"Anacor Pharmaceuticals. KerydinTM (tavaborole) topical solution, 5%., DrugsFDA FDA Approv. Drug Prod. 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204427s000lbl.pdf. Accessed 04 Feb 2020."},{"key":"580_CR49","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.18646.1","author":"AK Gupta","year":"2019","unstructured":"Gupta AK, Stec N. Recent advances in therapies for onychomycosis and its management. F1000Research. 2019. https:\/\/doi.org\/10.12688\/f1000research.18646.1.","journal-title":"F1000Research"},{"key":"580_CR50","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1177\/1203475417716362","volume":"21","author":"AK Gupta","year":"2017","unstructured":"Gupta AK, Versteeg SG, Shear NH. Onychomycosis in the 21st century: an update on diagnosis, epidemiology, and treatment. J Cutan Med Surg. 2017;21:525\u201339. https:\/\/doi.org\/10.1177\/1203475417716362.","journal-title":"J Cutan Med Surg."},{"key":"580_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2020.101774","author":"JJ Shen","year":"2020","unstructured":"Shen JJ, Jemec GBE, Arendrup MC, Saunte DML. Photodynamic therapy treatment of superficial fungal infections: a systematic review. Photodiagn Photodyn Ther. 2020. https:\/\/doi.org\/10.1016\/j.pdpdt.2020.101774.","journal-title":"Photodiagn Photodyn Ther"},{"key":"580_CR52","doi-asserted-by":"publisher","DOI":"10.4103\/ijdvl.IJDVL_853_18","author":"V Saoji","year":"2019","unstructured":"Saoji V, Madke B. Efficacy of salicylic acid peel in dermatophytosis. Indian J Dermatol Venereol Leprol. 2019. https:\/\/doi.org\/10.4103\/ijdvl.IJDVL_853_18.","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"580_CR53","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/ced.13780","volume":"44","author":"T-H Huang","year":"2019","unstructured":"Huang T-H, Lan C-CE. Cutaneous chromoblastomycosis effectively treated with local heat monotherapy. Clin Exp Dermatol. 2019;44:461\u20132. https:\/\/doi.org\/10.1111\/ced.13780.","journal-title":"Clin Exp Dermatol."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00580-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-020-00580-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00580-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T02:22:38Z","timestamp":1616034158000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-020-00580-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["580"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00580-6","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,22]]},"assertion":[{"value":"28 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"HJR and EMQ are employed by Mediprobe Research Inc., a not-for-profit, non-commercial research group and have no conflicts of interest that are directly relevant to the content of this article. AKG is a consultant for Bausch Health, Ortho Dermatologics, and Moberg Pharma; NHS has been a paid consultant to Alpha Laboratories, Canada & Bausch Health, Canada. VP has no personal financial ties with any pharmaceutical company. He undertakes advisory work for Pfizer, AbbVie, Janssen, UCB, Novartis, Almirall, and Celgene and has received honoraria from Kyowa Kirin Co., Ltd. In his role as Department Division Director of Dermatology at the University of Toronto, VP has received departmental support in the form of unrestricted educational grants from AbbVie, Bausch Health (formerly Valeant), Celgene, Janssen, LEO Pharma, Lilly, NAOS, Novartis, Pfizer, Pierre-Fabre, and Sanofi in the past 3 years.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The manuscript was conceived by AKG; the work was drafted by HJR and substantively revised by AKG, EQ, NHS, and VP.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s contributions"}}]}}